THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Saturday, October 15, 2022
The global pharmaceutical R&D outsourcing market is observing massive growth, with several transformative elements bringing new patterns to the process.
FREMONT, CA: In a world of dramatically growing information, highly sophisticated technology, and an unstable economic environment, pharmaceutical businesses are progressively outsourcing research to academia and private contract research organisations (CROs).
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The pharmaceutical R&D outsourcing market will grow as pharmaceutical and biotechnology companies spend more on outsourced services. Outsourced R&D activities span basic research through late-stage development, including genetic engineering, target identification and validation, assay creation, hit discovery and lead optimisation, safety and efficacy testing in animal studies, and human clinical trials. New transformations, primarily due to the pandemic, will change market structures, contributing to market growth.
Shift Towards Virtual Clinical Trials
Virtual or decentralised clinical trials bring significant digital changes to clinical research methods and enhance the patient-centric experience. These solutions include countless benefits like technology, advanced applications, electronic devices, online social engagement platforms, artificial intelligence (AI), robotic process automation, and machine learning (ML).
Patient recruitment and absenteeism are the most prominent causes of clinical delay. These delays cost a significant amount to pharmaceutical companies and sponsors. A complete digital or cross-model of patient enrolment is deployed in decentralised clinical trials. This helps reach the recruitment target easily and rapidly, easing the entire process and engaging.
The Emergence of Artificial Intelligence (AI) in Drug Discovery and Development
Artificial intelligence (AI) has numerous use cases in healthcare, especially in the pharmaceutical industry, where it is making a notable difference with its uses in drug discovery and development, clinical trials, and pharmaceutical productivity. A new drug’s life span from a lab to a store is a complex chain taking time and development. AI can minimise such difficult circumstances and achieve targets in a short time.
Many pharmaceutical businesses execute innovative technologies like AI and machine learning to derive high-quality results in a short time. In pharmaceutical product development, AI manages the drug design, decision-making, and therapy determination for patients with personalised medicines. Moreover, the generated clinical data is stored for future drug development.
Increasing Collaboration and Partnership Among CROs and Stakeholders
Several new models are emerging, and the primary innovation comes from the Clinical Research Organisation (CRO). CROs develop early chemical or biological entry points for the disease, approach potential interested firms, and collaborate on integrated drug discovery projects identified. Strategic partnerships are an essential pharmaceutical industry feature. Numerous in-and out-licences, joint research and development agreements exist between biopharmaceutical companies and academic research institutes.
More in News